Neumora Therapeutics, Inc.

NMRA · Nasdaq · United States

Share price · NMRA

$0.37-1.27 (-77.63%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.5M (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when NMRA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 2 Nov 2026+35.0%
  2. 16 Oct 2026+11.0%

    Nothing announced by NMRA that day or the session before.

  3. 15 Oct 2026+20.5%
  4. 13 Oct 2026-15.3%
  5. 30 Sep 2026-12.0%
  6. 22 Sep 2026+12.5%
  7. 15 Sep 2026-16.8%
  8. 16 Jun 2026+70.6%
  9. 15 Jun 2026-48.6%
  10. 14 May 2026+10.7%

Share of unusual movement by asset

For each asset, the share of NMRA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—54%
Sessions with no dated event—46%

No dated announcements about its assets since 2 Jul 2024.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1
Vasopressin V1a receptorSmall molecule
Alzheimer's Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

15 June 2026Topline resultnavacaprantKOASTAL-2 and KOASTAL-3 miss primary endpoints; navacaprant discontinued
Neumora Therapeutics · Source ↗
January 2025Topline resultnavacaprantPhase 3 KOASTAL-1 did not meet its primary or key secondary endpoints

Financial reports

Quarterly & interim (12)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$29M$117M$43M-$40M operating cash flowreport ↗
View 11 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1—$39M$147M$53M-$46M operating cash flowreport ↗
2025-Q3—$41M$129M+ $42M short-term inv.$57M-$47M operating cash flowreport ↗
2025-Q2—$39M$125M+ $93M short-term inv.$53M-$52M operating cash flowreport ↗
2025-Q1—$52M$127M+ $122M short-term inv.$68M-$59M operating cash flowreport ↗
2024-Q3—$61M$276M+ $66M short-term inv.$73M-$33M operating cash flowreport ↗
2024-Q2—$49M$151M+ $221M short-term inv.$59M-$56M operating cash flowreport ↗
2024-Q1—$46M$183M+ $240M short-term inv.$54M-$43M operating cash flowreport ↗
2023-Q3—$42M$412M+ $97M short-term inv.$53M-$48M operating cash flowreport ↗
2023-Q2—$33M$204M$39M-$31M operating cash flowreport ↗
2023-Q1—$29M$211M$36M-$33M operating cash flowreport ↗
2022-Q3—$23M$253M$29Mreport ↗

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$176M$183M$59M-$206M operating cash flowreport ↗

Neumora reported no revenue for FY2025, with no prior-year figure disclosed. R&D expense was $176.1M, down 12.4% YoY from $200.9M, while cash and cash equivalents totaled $182.5M at year-end. The company posted a full-year net loss of $236.9M, compared with $243.8M in 2024.

Management guided that the year-end cash position should fund operations into Q3 2027. Clinical highlights included new pre-specified Phase 1b data for NMRA-511 in Alzheimer’s disease agitation, full enrollment of the navacaprant KOASTAL-2 and -3 studies with a joint topline readout expected in Q2 2026, selection of NMRA-898 as the lead M4 franchise program in schizophrenia, and NMRA-215 preclinical data supporting a planned clinical start in Q1 2027.

View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$201M$142M+ $165M short-term inv.$61M-$183M operating cash flowreport ↗
2023-FY—$143M$374M+ $80M short-term inv.$59M-$163M operating cash flowreport ↗
2022-FY—$92M$241M+ $131M short-term inv.$33M-$115M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 15 sales ($784K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-21Aurora Daljit Singh · See RemarksOption exercise20,553$0.72$15KForm 4
2026-08-21Aurora Daljit Singh · See RemarksOpen-market sale20,553$1.59$33KForm 4
2026-08-21Aurora Daljit Singh · See RemarksOption exercise21,055$0.72$15KForm 4
2026-08-21Aurora Daljit Singh · See RemarksOpen-market sale21,055$1.60$34KForm 4
2026-08-21Aurora Daljit Singh · See RemarksOption exercise (derivative)20,553——Form 4
2026-08-21Aurora Daljit Singh · See RemarksOption exercise (derivative)21,055——Form 4
2026-08-20Pinto Joshua · director, President & CEOAward / grant (derivative)500,000——Form 4
2026-08-20Milligan Michael Lee · See RemarksAward / grant (derivative)175,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 114 reporting institutions held 70.4M shares ($135.6M, 37.5% of shares outstanding).

#InstitutionSharesValue
1Siren, L.L.C.8,497,822$16.6M
2SOFTBANK GROUP CORP.6,090,301$11.9M
3PERCEPTIVE ADVISORS LLC5,104,097$10.0M
4MIC Capital Management UK LLP4,460,700$8.7M
5VANGUARD CAPITAL MANAGEMENT LLC3,891,893$7.6M
6FMR LLC3,498,658$6.8M
7WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST3,309,123$6.5M
8MILLENNIUM MANAGEMENT LLC2,754,854$5.4M
9ICONIQ Capital, LLC2,559,090$5.0M
10Lunate Capital Ltd2,124,143$4.1M
11BlackRock, Inc.2,054,316$4.0M
12TWO SIGMA INVESTMENTS, LP2,036,692$4.0M
13JOHNSON & JOHNSON1,849,445$3.6M
14RENAISSANCE TECHNOLOGIES LLC1,388,998$2.7M
15Ikarian Capital, LLC1,278,408$2.5M